VidhiAagaz
International Journal ofLaw Management & Humanities
ISSN 2581-5369 · Open access
International Journal ofLaw Management & Humanities
Open accessResearch PaperVol. 5 No. I (2022)pp. 2502–2511

Critical Analysis of Natco Versus Bayer: An Eye Opener in India

DJ
Devi. JAssistant Professor at Chennai Dr. Ambedkar Govt. Law College, Pudupakkam, India
View PDF
1,073views742downloads
Published 28 February 2022 · pp. 2502–2511 · Vol. 5 No. I (2022)
Abstract

With the passage of the current Patents Act, inventors were given an exclusive right to their inventions if they fit certain criteria, such as being innovative, beneficial in industry, and not obvious to others. The monopoly granted by the government is only valid for a maximum of 20 years. During this moment, innovative thinkers have a window of opportunity to profit from their creations. For those who can afford it, a patented drug that has been introduced to the market by the creator or patentee is a superior option. The price of these patented drugs rises as a result of the patentee’s strict monopolistic policy or control. As a result, those in need must choose between purchasing lower-cost drugs, generics, or none at all. Because they couldn’t afford more expensive meds, they had no choice but to accept low-quality health care. Because they couldn’t afford more expensive medicines, they had no choice but to accept low-quality health care. From the standpoint of society and morals, such a result is neither acceptable nor ideal. It would be better for the patentee if a special relief plan was established that allowed patented pharmaceuticals to be supplied at a low price in emergency situations for the sake of society as a whole.

Keywords
NatcoBayerCompulsory licensingGATTPatent ActMonopoly

How to cite

Devi. J, Critical Analysis of Natco Versus Bayer: An Eye Opener in India, 5 Int'l J. L. Mgmt. & Human. 2502 (2022).

Cite this article

Devi. J, Critical Analysis of Natco Versus Bayer: An Eye Opener in India, 5 Int'l J. L. Mgmt. & Human. 2502 (2022).
Chat with us